BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors Of The Following Investigations: Diamond Hill Investment Group, Inc. (Nasdaq DHIL), Synchronoss Technologies (Nasdaq SNCR), Forge Global Holdings, Inc. (NYSE - FRGE), Hologic, Inc. (Nasdaq HOLX)
Diamond Hill Investment Group, Inc. (Nasdaq – DHIL)
Under the terms of the Merger Agreement, Diamond Hill will be acquired by First Eagle Investments (“First Eagle”) for $175 per share in an all-cash transaction valuing the Company at approximately $473 million. The investigation concerns whether the Diamond Hill Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Additional information can be found at .
Synchronoss Technologies (Nasdaq – SNCR)
Under the terms of the Merger Agreement, Synchronoss will be acquired by Lumine Group Inc. (“Lumine Group”) for $9.00 per share in cash in a transaction with an enterprise value of approximately $258.4 million. The investigation concerns whether the Synchronoss Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Additional information can be found at .
Forge Global Holdings, Inc. (NYSE - FRGE)
Under the terms of the Merger Agreement, Forge will be acquired by Charles Schwab Corporation (“Schwab”) for $45 cash per Common Share. The investigation concerns whether the Forge Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Additional information can be found at visit .
Hologic, Inc. (Nasdaq – HOLX)
Under the terms of the Merger Agreement, Hologic will be acquired by Blackstone in an all-cash transaction for $76 per share in cash plus a non-tradable contingent value right (CVR) to receive up to $3 per share in two payments of up to $1.50 each, for total consideration of up to $79 per share in cash. The non-tradable CVR would be issued to Hologic stockholders at closing and paid, in whole or in part, following achievement of certain global revenue goals for Hologic's Breast Health business in fiscal years 2026 and 2027. The investigation concerns whether the Hologic Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Additional information can be found at .
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment